BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

809 related articles for article (PubMed ID: 18068096)

  • 1. Dextran sulphate sodium induces acute colitis and alters hepatic function in hamsters.
    Karlsson A; Jägervall A; Pettersson M; Andersson AK; Gillberg PG; Melgar S
    Int Immunopharmacol; 2008 Jan; 8(1):20-7. PubMed ID: 18068096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation.
    Melgar S; Karlsson A; Michaëlsson E
    Am J Physiol Gastrointest Liver Physiol; 2005 Jun; 288(6):G1328-38. PubMed ID: 15637179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease.
    Melgar S; Karlsson L; Rehnström E; Karlsson A; Utkovic H; Jansson L; Michaëlsson E
    Int Immunopharmacol; 2008 Jun; 8(6):836-44. PubMed ID: 18442787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-1beta targets interleukin-6 in progressing dextran sulfate sodium-induced experimental colitis.
    Kwon KH; Murakami A; Hayashi R; Ohigashi H
    Biochem Biophys Res Commun; 2005 Nov; 337(2):647-54. PubMed ID: 16202978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis.
    Nam SY; Kim JS; Kim JM; Lee JY; Kim N; Jung HC; Song IS
    Exp Biol Med (Maywood); 2008 Feb; 233(2):180-91. PubMed ID: 18222973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dextran sulfate sodium-induced colitis generates a transient thymic involution--impact on thymocyte subsets.
    Fritsch Fredin M; Elgbratt K; Svensson D; Jansson L; Melgar S; Hultgren Hörnquist E
    Scand J Immunol; 2007 May; 65(5):421-9. PubMed ID: 17444952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice.
    Naito Y; Katada K; Takagi T; Tsuboi H; Isozaki Y; Handa O; Kokura S; Yoshida N; Ichikawa H; Yoshikawa T
    Int J Mol Med; 2006 Jun; 17(6):997-1004. PubMed ID: 16685407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the complement and contact systems in the dextran sulfate sodium-induced colitis model: the effect of C1 inhibitor in inflammatory bowel disease.
    Lu F; Fernandes SM; Davis AE
    Am J Physiol Gastrointest Liver Physiol; 2010 Jun; 298(6):G878-83. PubMed ID: 20338925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonmyeloablative stem cell therapy enhances microcirculation and tissue regeneration in murine inflammatory bowel disease.
    Khalil PN; Weiler V; Nelson PJ; Khalil MN; Moosmann S; Mutschler WE; Siebeck M; Huss R
    Gastroenterology; 2007 Mar; 132(3):944-54. PubMed ID: 17383423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrogen mediates suppression of colon inflammation induced by dextran sodium sulfate.
    Kajiya M; Silva MJ; Sato K; Ouhara K; Kawai T
    Biochem Biophys Res Commun; 2009 Aug; 386(1):11-5. PubMed ID: 19486890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis.
    Mikami S; Nakase H; Yamamoto S; Takeda Y; Yoshino T; Kasahara K; Ueno S; Uza N; Oishi S; Fujii N; Nagasawa T; Chiba T
    J Pharmacol Exp Ther; 2008 Nov; 327(2):383-92. PubMed ID: 18716065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of experimental colitis by intestinal mononuclear phagocytes.
    Qualls JE; Kaplan AM; van Rooijen N; Cohen DA
    J Leukoc Biol; 2006 Oct; 80(4):802-15. PubMed ID: 16888083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic study of dextran sulfate sodium experimental murine colitis.
    Cooper HS; Murthy SN; Shah RS; Sedergran DJ
    Lab Invest; 1993 Aug; 69(2):238-49. PubMed ID: 8350599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The opioid antagonist naltrexone improves murine inflammatory bowel disease.
    Matters GL; Harms JF; McGovern C; Fitzpatrick L; Parikh A; Nilo N; Smith JP
    J Immunotoxicol; 2008 Apr; 5(2):179-87. PubMed ID: 18569389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation by dietary taurine of dextran sulfate sodium-induced colitis in mice and of THP-1-induced damage to intestinal Caco-2 cell monolayers.
    Zhao Z; Satsu H; Fujisawa M; Hori M; Ishimoto Y; Totsuka M; Nambu A; Kakuta S; Ozaki H; Shimizu M
    Amino Acids; 2008 Jun; 35(1):217-24. PubMed ID: 17619120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice.
    Martín AR; Villegas I; Alarcón de la Lastra C
    Inflamm Res; 2005 Apr; 54(4):145-51. PubMed ID: 15883736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse strain differences in inflammatory responses of colonic mucosa induced by dextran sulfate sodium cause differential susceptibility to PhIP-induced large bowel carcinogenesis.
    Nakanishi M; Tazawa H; Tsuchiya N; Sugimura T; Tanaka T; Nakagama H
    Cancer Sci; 2007 Aug; 98(8):1157-63. PubMed ID: 17573895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis.
    Araki A; Kanai T; Ishikura T; Makita S; Uraushihara K; Iiyama R; Totsuka T; Takeda K; Akira S; Watanabe M
    J Gastroenterol; 2005 Jan; 40(1):16-23. PubMed ID: 15692785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model.
    Ghia JE; Blennerhassett P; Kumar-Ondiveeran H; Verdu EF; Collins SM
    Gastroenterology; 2006 Oct; 131(4):1122-30. PubMed ID: 17030182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new flavonoid derivative, dosmalfate, attenuates the development of dextran sulphate sodium-induced colitis in mice.
    Villegas I; Alarcón de la Lastra C; Orjales A; La Casa C
    Int Immunopharmacol; 2003 Dec; 3(13-14):1731-41. PubMed ID: 14636824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.